

## **ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726** SHEET 1 OF 6

## INFORMATION DISCLOSURE STATEMENT LIST

10/589,726 **Application Number** August 17, 2006 Filing Date Hawiger et al. First Named Inventor Group Art Unit 1647

Unassigned

Complete if Known

(Use as many sheets as necessary)

			J.S. PATENT (	DOCUMENTS			
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate
	A1	6,323,317	11/27/2001	Hilton et al.			
	A2	7,049,418	5/23/2006	Hilton et al.			
	A3	6,905,842	6/14/2005	Hilton et al.			

**Examiner Name** 

	AS	0,900,842	0/14/	2005		i et al.				
	A4	3,610,795	10/5/	1971	Antoi	ne, J.				
		FOR	REIGN	PATIEN	IT DO	<b>EUMENITS</b>	i de die	v	***	
Examiner's Initials	Cite No.	Foreign Patent Docume Country Code-Number-Kind Co		Dat	te		Name		Translation Yes/No	
	A5	WO 99/03993		1/28/19	99	Schering Corpo	oration			
	A6	EP0045665			Szelke et al					
		in	ON-P/	ATENT	DOCU	MENITS				
Examiner's Initials	Cite No.	Non-Patent	Citation	1S (include A	uthor, Title	, Publisher, Relevant Pa	ges, Date and P	lace of Publication	1)	
	A7	Abrahmsen L et al., "Engineering subtilisin and its subtrates for efficient ligation of peptide bonds in aqueous solutions," Biochemistry, 30:4151-4159 1991								
	A8	Alexander and Douglas J. Hilton. "The role of suppressors cytokine signaling (SOCS)" 22:503–29, 2004								
	A9	Alexander et al. "Suppri 2002	essors	of Cytok	ine sigr	naling Immune s	ystem," Na	t Rev (SOC	S) 2:1-7,	
	A10	Alexander, W.S., "Supp Immunol 2, 410-6, 2002		s of cytol	kine sig	nalling (SOCS) i	n the immu	ine system"	Nat Rev	
	A11	Almquist et al., "Synthe (1980)	sis and	l biologic	al activ	ity of a ketometh	ylene," J. I	Med. Chem 2	23:1392-1398	
	A12	Arad, G., Levy, R., Hillman, D. & Kaempfer, R. "Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation." Nat Med 6, 414-21 (2000).								
	A13	Baggiolini M et al. "Interleukin-8, a chemotactic and inflammatory cytokine," FEBS Lett. 307:97-101, 1992					tt. 307:97-			
	A14	Bagshawe, et al., "A cyl 58:700-703, (1988)	totoxic	agent ca	n be ge	enerated selectiv	ely at cand	ær sites." Br	. J. Cancer,	
	A15	<del></del>	First Ba	gshawe	lecture	Bagshawe, K.D., "The First Bagshawe lecture. Towards generating cytotoxic agents at cancer				

	sites." Br. J. Cancer, 60:275-281, (1989)	
A16	Balaban, N. & Rasooly, A. "Analytical chromatography for recovery of small amounts of staphylococcal enterotoxins from food." Int J Food Microbiol 64, 33-40 (2001).	
A17	Battelli, et al., "T lymphocyte killing by a xanthine-oxidase-containing immunotoxin." Cancer Immunol. Immunother., 35:421-425, (1992)	
A18	Benner, "Expanding the genetic lexicon: incorporating non-standard amino acids into proteins by ribosome-based synthesis." TIB Tech, 12:158-163 (1994)	
A19	Bjorbaek, C.et al. "The role of SOCS-3 in leptin signaling and leptin resistance." J. Biol. Chem.274, 30059-30065, 1999	
Examiner Signatur	Pate Considered:	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			plete if Known
INFORM	MATION DISCLOSURE	Application Number	10/589,726
S <sup>-</sup>	TATEMENT LIST	Filing Date	August 17, 2006
		First Named Inventor	Hawiger et al.
(Use a	s many sheets as necessary)	Group Art Unit	1647
		Examiner Name	Unassigned
A20	Brown and Greene, "Molecular and cellu	ular mechanisms of recept	or-mediated endocytosis." DNA
	and Cell Biology 10:6, 399-409 (1991)	·	
A21	Cahill et al., "Site-specific mutagenesis	with unnatural amino acids	s." TIBS, 14(10):400-403 (1989)
A22	Car, B.D. et al. "Interferon gamma receptor deficient mice are resistant to endotoxic shock." J Exp. Med 179, 1437-44 (1994).		
A23	Cavaillon, J.M., Adib-Conquy, M., Fitting Scand J Infect Dis 35, 535-44 (2003).	g, C., Adrie, C. & Payen, D	. "Cytokine cascade in sepsis."
A24	Clark Lewis I et al., "Chemical synthesis proteins, Neutrophil activating peptide 1 Biochemistry, 30:3128 (1991)	(interleukin-8) and neutro	phil activating peptid 2."
A25	Clark Lewis I et al., "Structural requirem analogs and CXC chemokine hybrids."	J.Biol.Chem., 269:16075-1	6081 (1994)
A26	Clark, N.M., Hershberger, E., Zervosc, I gram-positive organisms in the intensive		
A27	Croker, B.A. et al. "SOCS3 negatively re (2003).	egulates IL-6 signaling in v	ivo." Nat Immunol 4, 540-5
A28	Dawson et al. Synthesis of Proteins by Native Chemical Ligation. Science, 266:776 779, 1994		
A29	De Lisle Milton, R.C. et al., "Synthesis of Segments: Mirror-Image Enxyme Molec Chemistry IV. Academic Press, New Yo	cules, D- & L-HIV Protease	
A30	Dinges, M.M., Orwin, P.M. & Schlievert, Rev 13, 16-34, (2000).		/lococcus aureus." Clin Microbiol
A31	Drakas R et al. "A modified tandem affir complexes in mammalian cells." Proteor		ue for the purification of protein
A32	Emanuelli, B. et al, "SOCS-3 Is an insul Chem. 275, 15985-15991 (2000)		tor of insulin signaling." J.Biol.
A33	Fey, P.D. et al. "Comparative molecular resistant Staphylococcus aureus." Antin		
A34	Fitzgerald, K.A. et al. "LPS-TLR4 signal TRAM and TRIF." J Exp Med 198, 1043	-55 (2003).	
A35	Hann M. et al. "On the double bond isostere of the peptide bond: preparation of an enkephalin analogue." Chem. Soc Perkin, 307-314 (1982)		
A36	Hawiger, J. "Cellular import of functional Immunol 9, 189-94 (1997).		
A37	Hawiger, J. "Innate immunity and inflam 109 (2001).		
A38	Hawiger, J. "Noninvasive intracellular de Chem Biol 3, 89-94 (1999).		· · · · · · · · · · · · · · · · · · ·
A39	Hoebe, K. et al. "Identification of Lps2 a Nature 424, 743-8 (2003).	s a key transducer of MyD	88-independent TIR signaling."

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citati	ion is in conformance with MPEP 609. Draw line through citation if
not in conformance and not considered. Include conv of this form v	with next communication to applicant

	MATION DISCLOSURE TATEMENT LIST	Application Number Filing Date	plete if Known 10/589,726 August 17, 2006	
J	TATEMENT EIGT	First Named Inventor	Hawiger et al.	
(Use as many sheets as necessary)		Group Art Unit	1647	
		Examiner Name	Unassigned	
A40	Holladay et al. "Synthesis of hydroxye	ethlyene and ketomethylene		
17110	Tetrahedron." Lett 24:4401-4404 (19		dipopular isosio. et,	
A41	Hotamisligil, G. S., "Inflammatory path 55,(2003)		.S. Int. J. Obes 27, S53-	
A42	Hruby, "Conformational restrictions of Life Sci 31:189-199 (1982)	biologically active peptides	via amino acid chain groups."	
A43	Hudson, D. et al., "Methionine enkept support." Int J Pept Prot Res 14:177-	185 (1979)		
A44	Hughes et al.," Monoclonal antibody t Research, 49:6214-6220, (1989)	argeting of lipsomes to mous	se lung in vivo." Cancer	
A45	Ibba and Hennecke, "Towards engine natural amino acids." Bio/technology,	• • •	ed incorporated in vivo of non-	
A46		Ibba,M., "Strategies for in vitro and in vivo translation with non-natural amino acids."  Biotechnology & Genetic Engineering Reviews 13:197-216 (1995)		
A47	Itakura et al., "Synthesis and use of s			
A48	Inagaki-Ohara K, Hanada T, Yoshimura A., "Negative regulation of cytokine signaling and inflammatory diseases." Curr Opin Pharmacol. 3:435-42 2003.			
A49	Ivashkiv LB, Tassiulas I., "Can SOCS make arthritis better?" J Clin Invest.; 111, 795-7 2003			
A50	Jaeger et al., "Predicting optimal and suboptimal secondary structure for RNA." Methods Enzymol. 183:281-306, 1989			
A51	Jaeger et al., "Improved predictions o 86:7706-7710, 1989	f secondary structures for RI	NA." Proc. Natl. Acad. Sci. USA	
A52	Jennings-White et al., "Synthesis of k 23:2533-2534 (1982)	ketomethylene analogs of dip	peptides." Tetrahedron Lett	
A53	Jo et al., "Intracellular Protein Therap Med., 11, 892-898 2005	y with SOCS3 Inhibits Inflam	mation and Apoptosis." Nature	
A54	Jo, D. et al., "Cell cycle-dependent tra Cell Biochem 89, 674-87 (2003).	ansduction of cell-penetrating	g Cre recombinase proteins." J	
A55	Jo, D. et al., "Epigenetic regulation of recombinase." Nat Biotechnol 19, 929	9-33 (2001).	•	
A56	Krebs, D.L. & Hilton, D.J. "SOCS prot 19, 378-87 (2001).			
A57	Krebs, D.L. & Hilton, D.J. "SOCS: phy 2813-9 (2000).			
A58	Kunkel et al. "Rapid and efficient site- Enzymol. 1987:154:367, 1987	specific mutagenesis withou	t phenotypic selection." Method	
A59	Lang, R. et al., "SOCS3 regulates the	plasticity of gp130 signaling	." Nat Immunol 4, 546-50 (2003	
A60	Larsen et al., "Suppressors of Cytokir 12, pages 833-844			
A61	Lee, J.Y. & Sullivan, K.E., "Gamma in transcription to induce tumor necrosis			
ner Signatu		Date Considered:		

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	<u> </u>	Com	plete if Known
INFORM	MATION DISCLOSURE	Application Number	10/589,726
	TATEMENT LIST	Filing Date	August 17, 2006
		First Named Inventor	Hawiger et al.
(Use a	(Use as many sheets as necessary)		1647
		Group Art Unit Examiner Name	Unassigned
A62	Letsinger et al., "Cholesteryl-conjugated	d oligonucleotides: Synthe	
702	inhibitors of replication of human immun		
	86, 6553 6556, 1989	,	,
A63	Litzinger and Huang, Biochimica et Biop	hysica Acta, 1104:179-18	7, (1992)
A64	Liu, D. et al. "Suppression of Staphyloco	occal Enterotoxin B-induce	d Toxicity by a Nuclear Import
	Inhibitor." J Biol Chem 279, 19239-46 (2		
A65	Madsen, J.M. "Toxins as weapons of ma		
	warfare and chemical-warfare agents."		
A66	Mattix, M.E., Hunt, R.E., Wilhelmsen, C		
	staphylococcal enterotoxin B-induced pr	ulmonary lesions in rhesus	monkeys (Macaca mulaπa).
A67	Toxicol Pathol 23, 262-8 (1995).  Miethke, T. et al. "T cell-mediated lethal	shock triggored in mice by	the superantigen
Ao/	staphylococcal enterotoxin B: critical rol	• • • • • • • • • • • • • • • • • • • •	•
A68	Morley, "Modulation of the Action of reg		
1 700	Sci pp. 463-468,1980	diatory populace by structu	Tar modification. Trende i nami
A69	Narang et al., "Chemical synthesis of Do	exoxvoligonucleotides by t	he modified trimester method."
	Methods Enzymol., 65:610-620 (1980)	, <u>-</u>	
A70	Needleman and Wunsch, "A general me	ethod applicable to the sea	rch for similarities in the amino
	acid sequence of two proteins." J. MoL		
A71	Nielsen et al., "Petide nucleic acid (PNA	<ol> <li>A DNA mimic with a per</li> </ol>	otide backbone." Bioconjug.
	Chem. 5:3-7 (1994)		
A72	NIH Grant No. HL68744. "Functional G		
A73	NIH Grant No. HL69542. "Superantigen		
A74	O'Keefe, G.M., Nguyen, V.T., Ping Tang		
	II transactivator promoter IV in macroph		ement of the suppressors of
A75	cytokine signaling-1 protein." J Immuno Oshiumi, H. et al. "TIR-containing adapt		bridging adaptor recruiting to tell-
Ars	like receptor 4 TICAM-1 that induces int	· · · · · · · · · · · · · · · · · · ·	
A76	Pearson and Lipman, "Improved tools for		
1 1110	U.S.A. 85: 2444 - 2448 (1988)	or biological orqueille	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A77	Pfeffer, K. et al., "Mice deficient for the	55 kd tumor necrosis factor	r receptor are resistant to
	endotoxic shock, yet succumb to L. mor	nocytogenes infection." Ce	ll 73, 457-67 (1993).
A78	Pietersz and McKenzie, "Antibody conju	igates for the treatment of	cancer." Immunolog. Reviews,
	129:57-80, (1992)		
A79	Poltorak, A. et al. "Defective LPS signal gene." Science 282, 2085-8 (1998).	ing in C3H/HeJ and C57Bl	_/10ScCr mice: mutations in Tlr4
A80	Prescilla et al. http://www.emedicine.com 2003)	m, Immunology of Transpla	ant Rejection, updated June 20,
A81	Rajagopalan, G., Smart, M.K., Krco, C.		
}	HLA-DQ molecules and lymphocyte dev	velopment in mice lacking i	nvariant chain." J Immunol 169,
	1774-83 (2002).		

Examiner Signature:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Com	plete if Known
INFORM	IATION DISCLOSURE	Application Number	10/589,726
	ATEMENT LIST	Filing Date	August 17, 2006
		First Named Inventor	Hawiger et al.
(Use as	s many sheets as necessary)	Group Art Unit	1647
		Examiner Name	Unassigned
A82	Rizo and Gierasch, "Constrained peptid	es: models of bioactive pe	ntides and protein
1 7.02	substructures." Ann. Rev. Biochem. 61:	•	padoo ama protom
A83	Roffler, et al., "Anti-neoplastic glucuroni		man tumor cells targeted with a
	monoclonal-enzyme conjugate." Bioche		
A84	Rottapel R., "Putting the brakes on arth-		
	suppress rheumatoid arthritis?" J Clin Ir		
A85	Rui, L., Yuan, M., Frantz, D., Shoelson,		
	signaling by ubiquitin-mediated degrada		
A86	Sambrook et al., Molecular Cloning: A L		, , ,
	Laboratory Press, Cold Spring Harbor, I	N.Y., 1989) Chapter 5 "Enz	zymes Used in Molecular
407	Cloning"	abaratan Manual 2nd Ed	High (Cold Spring Harbor
A87	Sambrook et al., Molecular Cloning: A L Laboratory Press, Cold Spring Harbor, I		
A88	Schnolzer, M et al., "Constructing protein		
700	Backbone-engineered HIV protease." S		ited synthetic populacs.
A89	Senter, et al., "Generation of 5-flouroura		v monoclonal antibody-cytosine
	deaminase conjugates." Bioconjugate		,, 0,
A90	Senter, et al., "Generation of cytotoxic a		s." Bioconjugate Chem., 4:3-9,
	(1993)		
A91	Shouda, T. et al., "Induction of the cytol		
	for treating inflammatory arthritis." J Clir		
A92	Smith and Waterman, Comparison of bi		
A93	Spatola et al., "Structure-activity relation	•	• • •
104	thimethylene amide bond surrogates." L		
A94	Spatola, A. F., Vega Data (March 1983)		
	Structure-Activity Analysis of Peptides (5., pages 267 - 357	Containing Amide bond Su	rrogates. (general review), Chap
A95	Starr R, Hilton DJ SOCS: suppressors of	of cytokine signaling. Int .I.I	Riochem Cell Riol 30(10):1081-5
733	(1998 Oct).	or cytokine signaling. Into	Siconem Cen Biol.co (10). 1001 0
A96	Starr, R. et al. "A family of cytokine-indu	cible inhibitors of signaling	ı." Nature 387, 917-21 (1997).
A97	Stoiber, D. et al. "Lipopolysaccharide in		
	cytokine signaling 3 and suppresses sig		
	gamma." J Immunol 163, 2640-7 (1999)	-	G
A98	Suzuki, A. et al. "CIS3/SOCS3/SSI3 pla	ys a negative regulatory ro	ole in STAT3 activation and
	intestinal inflammation." J Exp Med 193		
A99	Thorson et al., "A Biosynthetic Approac	•	Innatural Amino Acids Into
	Proteins" Methods in Molecular Biology		
A100	Uysal, K.T. et al, "Protection from obesi	ty-induced insulin resistand	ce in mice lacking TNF function."
1404	Nature 389:610-614 1997	indoponios torreties -f	functional partides acres the
A101	Veach, R.A. et al. "Receptor/transporter	,	unctional peptides across the
	plasma membrane." J Biol Chem 279, 1	1420-01 (2004).	

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citat	ion is in conformance with MPEP 609. Draw line through citation if
not in conformance and not considered. Include conviol this form to	with next communication to applicant

			Com	plete if Known
1		ATION DISCLOSURE	Application Number	10/589,726
INFORMATION DISCLOSURE STATEMENT LIST			Filing Date	August 17, 2006
	31	ATEMENT EIST	First Named Inventor	
	(Use as	many sheets as necessary)	Group Art Unit	1647
	(	<b>,</b> ,	Examiner Name	Unassigned
	A 4 0 0	Vacuala C. Nagaki M. 9 Maniughi II	I	<u> </u>
	A102	Yasuda, S., Nagaki, M. & Moriwaki, H., lethal shock in endotoxin-resistant C3H, Endotoxin Res 8, 253-61 (2002).	/HeJ mice despite a deficie	ent macrophage response." J
	A103	Yasukawa, H. et al. "IL-6 induces an an macrophages." Nat Immunol 4, 551-6 (2		n the absence of SOCS3 in
	A104	Yasukawa, H., Sasaki, A. & Yoshimura, Annu Rev Immunol 18, 143-64 (2000).	, A. "Negative regulation of	cytokine signaling pathways."
	A105	Yeung, R.S. et al. "Human CD4 and hur transgenic mice: supersensitivity to sup 82 (1996).	erantigen-induced septic s	hock." Eur J Immunol 26, 1074-
	A106	Zhang, J.G. et al. "The SOCS box of su of cytokine action in vivo." Proc Natl Act		
	A107	Zoller, "New recombinant DNA methodo Biotechnology, 3:348-354 (1992)	ology for protein engineering	g." Current Opinion in
	A108	Zuker, "On finding all suboptimal folding	gs of an RNA molecule." N	I. Science 244:48-52, 1989
-				
			<u></u>	
L				

Examiner Signature:	Date Considered:				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if					
not in conformance and not considered. Include copy of this form with next communication to applicant.					